Evidence map›Paper›PMID 39588174›Full record

ArticleUS cardiology2024

Successful Percutaneous Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a High-risk Patient with Cardiorenal Syndrome.

Deniz Mutlu, Ibrahim Halil Inanc, Ozgecan Piril Zanbak Mutlu, Konstantinos Marmagkiolis, Cezar A Iliescu, Mehmet Cilingiroglu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in US cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Deniz MutluDepartment of Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa Istanbul, Turkey.
Ibrahim Halil InancDepartment of Cardiology, Kirikkale Yuksek Ihtisas Hospital Kirikkale, Turkey.
Ozgecan Piril Zanbak MutluDepartment of Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa Istanbul, Turkey.
Konstantinos MarmagkiolisDepartment of Cardiology, MD Anderson Cancer Center, University of Texas Houston, TX.
Cezar A IliescuDepartment of Cardiology, MD Anderson Cancer Center, University of Texas Houston, TX.
Mehmet CilingirogluDepartment of Cardiology, MD Anderson Cancer Center, University of Texas Houston, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients. In this report, we describe the successful treatment of an 84-year-old male patient suffering from severe symptomatic AR and concomitant cardiorenal syndrome with renal failure using a 34 mm Evolut R (Medtronic) self-expanding transcatheter aortic valve replacement. This intervention resulted in the resolution of AR, cardiorenal syndrome, and congestive heart failure symptoms.

Indexed as

Aortic regurgitationcardiorenal syndrometranscatheter aortic valve replacement

Identifiers

PMID39588174
PMCPMC11588104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.